Factor V Leiden is a specific inherited change in the F5 gene that increases susceptibility to venous blood clots. It is most strongly associated with deep vein thrombosis in the leg and pulmonary embolism, not with the ordinary arterial clots that cause most heart attacks and strokes. The genetic test can show whether a person carries one copy or two copies of the variant, but it cannot diagnose an active clot or predict exactly whether one will ever occur. Most heterozygous carriers never develop venous thromboembolism, while risk rises when the variant is combined with surgery, immobility, estrogen exposure, pregnancy, obesity, increasing age, cancer, or another thrombophilia. Testing is useful only when the result is likely to change a decision about prevention, hormone use, pregnancy management, or family counseling. It should not be ordered automatically after every clot. Treatment duration is usually driven more by whether the clot was provoked, recurrence risk, bleeding risk, and patient preferences than by Factor V Leiden status alone.
- Factor V Leiden is the F5 c.1601G>A variant, historically called R506Q and now commonly described as p.Arg534Gln.
- The test identifies inherited susceptibility; ultrasound, CT imaging, and blood tests evaluate an active clot.
- One copy raises venous clot risk modestly, while two copies generally confer higher risk.
- A positive result does not mean lifelong anticoagulation is automatically needed.
- Testing often adds little after a clearly provoked clot if the result will not change management.
- Estrogen, pregnancy, surgery, immobility, and family history can be more important than genotype alone in a particular situation.
Table of Contents
- What Factor V Leiden changes
- Clots associated with the variant
- When testing may help
- How the test is performed
- Understanding heterozygous, homozygous, and negative results
- Treatment after a clot
- Pregnancy, estrogen, surgery, and travel
- Family testing and risk reduction
What Factor V Leiden changes
The F5 gene provides instructions for coagulation factor V, a protein that helps generate thrombin and form fibrin during normal clotting. Once a clot has done its job, natural anticoagulant pathways limit further growth. Activated protein C normally cuts and inactivates factor Va at specific sites. The Factor V Leiden variant alters one of those sites, making factor V relatively resistant to activated protein C.
This resistance does not cause constant clotting. It shifts the balance toward coagulation, especially when another risk factor is present. The effect is therefore described as thrombophilia—a predisposition to thrombosis—rather than a clot itself. Many carriers go through life without venous thromboembolism.
The variant has several names. Modern laboratory reports may list F5 c.1601G>A and p.Arg534Gln, while older reports often use c.1691G>A or p.Arg506Gln because of a different numbering convention. “Factor V Leiden,” “FVL,” and the single-nucleotide identifier rs6025 usually refer to the same change. The exact nomenclature on the report matters when results are shared between laboratories or relatives.
Factor V Leiden is most common in people with European ancestry and is less frequent in many African, East Asian, and Indigenous populations. Ancestry affects the chance of carrying it but should not replace a clinical assessment. A person of any background may have the variant, and someone without it can still develop venous thromboembolism from other inherited or acquired causes.
Inheritance is autosomal dominant in the sense that one copy raises susceptibility. A heterozygous person has one altered F5 copy and one usual copy. A homozygous person has two Factor V Leiden copies and typically faces a greater risk. Rarely, a person inherits Factor V Leiden on one F5 copy and another pathogenic F5 change on the other; this can create a different and sometimes more substantial thrombotic phenotype.
Factor V Leiden is only one part of clot risk. The prothrombin F2 c.*97G>A variant, deficiencies of antithrombin, protein C, or protein S, antiphospholipid syndrome, cancer, inflammatory disease, age, body weight, estrogen, pregnancy, and transient provoking events can alter the overall picture. A genotype result should be interpreted within this combined risk profile.
Clots associated with the variant
The strongest association is with venous thromboembolism, particularly deep vein thrombosis of the legs and pulmonary embolism. A deep vein thrombosis may cause unilateral swelling, pain, warmth, or discoloration, although some clots are silent. A pulmonary embolism can cause sudden shortness of breath, chest pain, rapid heart rate, fainting, low oxygen, or coughing blood. These symptoms require urgent medical assessment.
Factor V Leiden can contribute to thrombosis at unusual venous sites, but the association is generally weaker and clinical context is important. Cerebral venous sinus thrombosis, splanchnic vein thrombosis, and upper-extremity thrombosis have multiple potential causes. Testing decisions in these situations often involve a hematologist because the result may or may not change anticoagulation.
The variant is not considered a major cause of ordinary arterial thrombosis. Most myocardial infarctions and ischemic strokes arise from atherosclerosis, plaque rupture, atrial fibrillation, hypertension, diabetes, smoking, and other arterial mechanisms. Finding Factor V Leiden after an arterial event does not prove causation and should not distract from established cardiovascular risk management.
Absolute risk varies widely. A healthy young heterozygous carrier with no family history and no provoking exposure may have a low annual risk. The same genotype during major surgery, prolonged immobilization, pregnancy, or estrogen therapy can become much more relevant. Homozygous carriers and people with combined thrombophilias generally warrant more individualized planning.
Family history adds information that the genotype alone cannot capture. A carrier from a family with several early, recurrent, or unprovoked clots may face a different practical risk from a carrier discovered incidentally in a family without thrombosis. Shared environmental factors and additional genetic contributors may account for part of that difference.
Pregnancy complications have been studied in relation to Factor V Leiden, but associations with recurrent miscarriage, preeclampsia, fetal growth restriction, or placental abruption are inconsistent and generally weaker than the association with maternal venous thrombosis. Routine testing solely for common pregnancy complications is not automatically beneficial. Obstetric history, personal clot history, and family history should guide evaluation.
When testing may help
The central question is whether knowing the result would change care. Modern thrombophilia guidelines discourage indiscriminate testing because many results do not alter treatment and can cause anxiety, unnecessary anticoagulation, or misleading reassurance. A clotting history should be classified before the test is ordered.
A provoked clot occurs after a major transient factor such as surgery, significant trauma, prolonged hospitalization, or immobilization. An unprovoked clot occurs without an obvious major trigger. Hormone-associated, pregnancy-associated, cancer-associated, and unusual-site thromboses have their own contexts. Recurrence risk and treatment decisions differ among these groups.
Testing may be considered in selected younger patients with venous thromboembolism, recurrent events, thrombosis at unusual sites, or a strong family history, particularly when the result could influence decisions about stopping anticoagulation, future prophylaxis, estrogen use, or pregnancy. Even in these groups, testing is not automatically indicated. The clinician should specify the management decision that depends on the answer.
A broad thrombophilia panel may include Factor V Leiden, the prothrombin variant, antithrombin activity, protein C, protein S, and antiphospholipid antibodies. These tests are not interchangeable. Anticoagulants, pregnancy, acute thrombosis, liver disease, and inflammation can distort several protein-based assays, while the DNA result for Factor V Leiden is stable and can be measured at any time. Timing still matters because ordering during an acute event may lead to an unfocused battery of tests that will not affect immediate treatment.
Testing is usually not needed merely because a person is starting a routine short course of travel, has varicose veins, or has a distant relative with a clot at an advanced age. It is also not a standard screening test for the general population. Testing every woman before prescribing estrogen is not universally recommended; personal and family history often identify risk more efficiently.
Relatives should not be tested simply because the variant exists in the family unless the result will guide a concrete decision. Selective testing may be reasonable before estrogen exposure or pregnancy in families with homozygous Factor V Leiden, combined thrombophilia, or a particularly strong VTE history. Hematology or genetics counseling can help determine whether the result would change prophylaxis.
Testing after an arterial stroke, heart attack, or pregnancy loss alone is frequently low yield unless venous thrombosis or another specific indication is present. MTHFR testing should not be added as a routine inherited thrombophilia test because common MTHFR variants do not have the same clinical meaning and generally do not guide VTE management.
How the test is performed
Factor V Leiden testing can be performed with a DNA assay or, in some settings, with an activated protein C resistance test followed by genetic confirmation. A DNA test usually uses blood, saliva, or a cheek-swab sample. Fasting is not required. Because the genotype does not change over a lifetime, a valid test normally needs to be performed only once.
Targeted genotyping looks specifically for the Factor V Leiden variant. Some laboratories test it together with the prothrombin F2 variant. Full F5 sequencing is not needed for routine Factor V Leiden detection and may uncover other variants that require different interpretation. The report should clearly state whether zero, one, or two copies were found.
Anticoagulant medication does not alter the DNA sequence, so warfarin, heparin, and direct oral anticoagulants do not invalidate a genetic result. They can interfere with some functional thrombophilia assays, however. The clinician may therefore separate the timing of the Factor V Leiden DNA test from protein C, protein S, antithrombin, or lupus anticoagulant testing.
An active clot is not diagnosed by genetic testing. Suspected deep vein thrombosis is evaluated with clinical assessment, D-dimer in appropriate settings, and compression ultrasound. Suspected pulmonary embolism may require CT pulmonary angiography, ventilation-perfusion scanning, or other urgent testing. A person should not wait for a genetic result before seeking care for symptoms.
Laboratory errors are uncommon with validated targeted assays, but unexpected direct-to-consumer or raw-data results should be confirmed in a clinical laboratory. The report should use recognized nomenclature and distinguish heterozygous from homozygous status. If the result appears inconsistent with prior family testing, the laboratory can review sample identity, assay design, and the exact familial variant.
Genetic counseling is usually brief but useful. It explains inheritance, the difference between relative and absolute risk, the effect of provoking factors, and why a positive result does not necessarily change anticoagulation. The result should be placed in the medical record with a concise management plan rather than treated as an emergency diagnosis.
Understanding heterozygous, homozygous, and negative results
A heterozygous result means one Factor V Leiden copy was detected. This is the most common positive result. It raises the relative risk of a first venous clot, but the absolute risk for an individual may remain low. Most heterozygous carriers do not need daily anticoagulation merely because of the genotype. Their care focuses on recognizing temporary risk periods and making individualized decisions about estrogen, pregnancy, surgery, and prior VTE.
A homozygous result means two copies were detected. Homozygous carriers generally have a higher risk than heterozygous carriers, especially when additional risk factors are present. This result may influence counseling and prophylaxis more strongly, but it still does not prove an active clot or automatically mandate lifelong anticoagulation in someone who has never had thrombosis.
A negative result means the Factor V Leiden variant was not found. It does not exclude other inherited or acquired thrombophilias and does not make future venous thrombosis impossible. Common provoking factors still apply. A negative result after a personal or strong family history should not be interpreted as permission to ignore surgery, immobility, estrogen, pregnancy, cancer, or prior clot history.
Rarely, a laboratory may report another F5 variant. Its significance cannot be inferred from the Factor V Leiden literature. Some F5 changes cause bleeding rather than thrombosis, while others may alter activated protein C resistance. Full sequencing findings require specialized interpretation based on the exact variant and phenotype.
The result should be separated from recurrence prediction. After a first VTE, recurrence risk depends greatly on whether the event was provoked, whether a persistent risk factor remains, clot location, sex, D-dimer and other clinical variables, and bleeding risk. Heterozygous Factor V Leiden alone usually has limited influence on duration decisions compared with these factors.
A result can also be misunderstood in families. A parent with one copy can pass either the altered or usual copy to each child, giving a 50% chance per pregnancy. Two heterozygous parents can have a child with two copies. The genotype does not “skip” generations in a predictable pattern, and the severity in one relative does not forecast the severity in another.
Treatment after a clot
Acute deep vein thrombosis and pulmonary embolism are treated according to standard VTE protocols. Depending on the clinical situation, anticoagulation may use a direct oral anticoagulant, low-molecular-weight heparin, unfractionated heparin, or warfarin. Severe pulmonary embolism may require thrombolysis, catheter intervention, or surgery. The immediate treatment is based on clot severity, location, kidney and liver function, pregnancy status, cancer, bleeding risk, and drug interactions—not on waiting for Factor V Leiden testing.
The duration of anticoagulation is individualized. A clot provoked by a major transient risk factor often receives a finite course if the trigger has resolved and bleeding risk is acceptable. An unprovoked or recurrent clot, a persistent risk factor, or selected unusual-site thrombosis may lead to extended treatment. Factor V Leiden status can contribute to the discussion but usually does not control it by itself.
A heterozygous carrier with a single surgery-provoked clot is not automatically treated for life. Conversely, a person without Factor V Leiden may need indefinite anticoagulation after recurrent unprovoked pulmonary emboli. This distinction prevents both overtreatment and false reassurance.
Anticoagulation carries bleeding risk. Decisions should consider prior bleeding, age, kidney function, other medications, fall risk, menstrual bleeding, occupation, and patient preferences. Lower-dose extended regimens may be appropriate for some patients, while others need full-dose therapy. These are hematology or thrombosis-care decisions.
A person who has had a VTE should keep a record of the event, provoking factors, imaging, medication course, and genetic results. Future clinicians need to know the clot history even if anticoagulation has ended. Temporary prophylaxis may be recommended during major surgery, hospitalization, or prolonged immobilization.
Compression stockings are not a substitute for anticoagulation in acute DVT, although they may help selected patients with symptoms. Aspirin is not equivalent to anticoagulant therapy for treatment of VTE. A positive Factor V Leiden result should never prompt self-starting aspirin or borrowed anticoagulants.
Pregnancy, estrogen, surgery, and travel
Pregnancy and the postpartum period increase venous clot risk even without thrombophilia. Management for a Factor V Leiden carrier depends on whether there has been a prior VTE, whether the person is heterozygous or homozygous, family history, cesarean delivery, obesity, immobility, and other factors. Some people need antepartum or postpartum low-molecular-weight heparin; others need clinical vigilance without routine medication. Planning should occur before pregnancy when possible.
A prior estrogen-associated or pregnancy-associated VTE has greater significance than genotype alone. Anticoagulation choices also differ during pregnancy because direct oral anticoagulants and warfarin are generally avoided in many pregnancy settings. Postpartum duration and breastfeeding-compatible options should be discussed with obstetric and hematology teams.
Combined estrogen-containing contraceptives and oral menopausal hormone therapy increase VTE risk. A Factor V Leiden carrier—especially someone with prior VTE, homozygosity, or a strong family history—should discuss nonestrogen contraception or alternative hormone routes and doses. Decisions should balance clot risk, bleeding, bone health, menopausal symptoms, and reproductive goals. Estrogen should not be started or stopped solely from an internet risk estimate.
Major surgery, hospitalization, fractures, casts, and prolonged immobility can create temporary high-risk periods. The surgical team should know the personal clot history and genotype. Prevention may include early mobilization, mechanical compression, and anticoagulant prophylaxis based on the procedure and bleeding risk. Routine long-term anticoagulation between such events is not always needed.
Long-distance travel causes a smaller risk increase than major surgery but can matter when several factors combine. Regular movement, calf exercises, hydration, and avoiding excessive sedatives may be advised. Compression stockings or medication are reserved for selected higher-risk travelers. A Factor V Leiden carrier with no prior VTE usually does not need anticoagulant injections for every flight.
Smoking cessation, maintaining a healthy weight, and staying active reduce several cardiovascular risks and may lower the number of acquired clot triggers. These measures do not “reverse” the genotype, but they improve the overall risk environment.
Family testing and risk reduction
Factor V Leiden is inherited in an autosomal pattern. A heterozygous carrier has a 50% chance of passing the variant to each child. Siblings may also be carriers if a parent carries it. The decision to test relatives should be based on whether the answer will change management, not simply on curiosity or a desire to label the family.
Testing may be useful for selected adult relatives considering estrogen, pregnancy, or a high-risk procedure, especially when the family includes homozygous carriers, combined thrombophilia, or multiple early unprovoked clots. In other families, counseling based on the family history may lead to the same precautions without testing. Children are generally not tested routinely because childhood VTE is rare and the result often does not change care; exceptions depend on unusually strong risk contexts.
Relatives should know the signs of DVT and pulmonary embolism regardless of testing. Sudden one-sided leg swelling, unexplained shortness of breath, chest pain, fainting, or coughing blood needs urgent assessment. A family history should be communicated before surgery, pregnancy, or hormone treatment.
A positive result should not lead to fear of ordinary movement. Regular activity is generally protective, while prolonged immobility raises risk. Carriers do not need to avoid all travel, pregnancy, surgery, or contraception; they need informed planning tailored to their overall risk.
A negative relative is not immune to VTE. Noncarriers share many acquired risks and may inherit other susceptibility factors. Likewise, a positive relative is not destined to clot. Clear counseling avoids turning a common risk variant into a disease identity.
The most useful result is one connected to a specific decision. For a person with VTE, that may be a discussion about future prophylaxis or hormones. For a relative, it may be pregnancy planning. When the result cannot change management, careful clinical history may be more valuable than testing.
References
- ASH VTE Guidelines: Thrombophilia Testing (2023 Guideline)
- American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing (2023 Guideline)
- Factor V Leiden Thrombophilia (2024 GeneReviews)
- Venous thromboembolism laboratory testing (factor V Leiden and factor II c.*97G>A): a technical standard of the American College of Medical Genetics and Genomics (ACMG) (2025 Technical Standard)
- Addendum: American College of Medical Genetics consensus statement on factor V Leiden mutation testing (2021 Consensus Update)
Disclaimer
This article provides general education and is not individualized advice about anticoagulation, hormones, pregnancy, surgery, or thrombophilia testing. Decisions should be made with a qualified clinician using personal VTE history, provoking factors, bleeding risk, medications, and family history. Sudden shortness of breath, chest pain, fainting, coughing blood, or one-sided leg swelling requires urgent medical evaluation.
